NovoCure Ltd
NVCRHeld by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase3 readout (Pembrolizumab): Oct 2028. Short interest: 13.0% of float.
Held by 4 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying4 funds opened new positions. Next phase3 readout (Pembrolizumab): Oct 2028. Short interest: 13.0% of float.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)
4 specialist funds hold NVCR with a Phase 3 in 748 days for Pembrolizumab (Metastatic Non-small Cell Lung Cancer)
+1 more upcoming catalyst
Position history (shares)
Rock Springs Capital, a healthcare-specialist long/short fund, fully exited its position in NovoCure (NVCR), a notable departure ahead of two major phase 3 readouts — Tumor Treating Fields combined with temozolomide in glioblastoma (2029) and pembrolizumab in metastatic NSCLC (2028). The exit signals waning conviction from a specialist that would typically be well-positioned to hold through binary catalyst risk of this nature.
2 quarters
Feb 13, 2026
$0
0 funds
Feb 17, 2026
$0
0 funds
May 15, 2026
$0
0 funds
Aug 14, 2026
$0
0 funds
-100% total institutional value over 15 quarters
Short Shares
11.16M
Change
+3.5%
Days to Cover
10.3
% of Float
13.0%
Settlement
Sep 30, 2026
Short interest over 12 periods
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.
# Summary for NVCR Investors This biochemistry study reveals that temozolomide (TMZ)—a standard chemotherapy agent used alongside Novocure's Tumor Treating Fields (TTF) in glioblastoma treatment—causes off-target RNA alkylation that suppresses protein translation, potentially explaining both its therapeutic efficacy and toxicity profile. The findings could have clinical implications for optimizing TMZ dosing regimens or combination strategies with TTF, though the research is preliminary (preprint) and focused on mechanism rather than clinical validation. For investors, this warrants monitoring whether the data influences treatment protocols in ongoing NVCR studies or suggests opportunities to differentiate TTF as a synergistic partner to chemotherapy by minimizing toxicity.
# NovoCure Investment Summary **Key Finding:** CD47 blockade combined with anti-GD2 therapy showed enhanced tumor cell phagocytosis in laboratory settings but failed to translate into improved survival or tumor control in live animal models of chemoresistant neuroblastoma. **Investor Implication:** This negative preclinical result suggests that CD47 checkpoint inhibition may have limited clinical utility as an adjunct to anti-GD2 immunotherapy in neuroblastoma—a potential pipeline strategy. The in vitro/in vivo disconnect indicates that combination approaches require careful validation and raises questions about whether similar combinations currently in development will face comparable translational hurdles, potentially affecting pipeline confidence and future licensing opportunities in this indication.
# Investment Summary: NVCR-Relevant Research This preprint identifies HDAC6 inhibition as a potential therapeutic approach to overcome temozolomide (TMZ) resistance in glioblastoma, a mechanism that could complement or enhance existing standard-of-care treatments. The finding is relevant to NovoCure's glioblastoma franchise as it suggests a potential combination strategy with Tumor Treating Fields (TTF), which is already used alongside TMZ in newly diagnosed glioblastoma—a resistance-management pathway could expand the addressable patient population and improve durability of response. However, as a preprint without peer review or in vivo validation, clinical utility remains unproven and would require formal development; investors should monitor whether NVCR or partners pursue HDAC6-based combinations in upcoming trials.
# Investment Summary: NovoCure (NVCR) - Temozolomide Research **Clinical/Commercial Relevance:** This preclinical finding of off-target antidepressant-like effects from temozolomide (a standard chemotherapy agent) is unlikely to create meaningful near-term value for NovoCure, as NVCR's core business centers on Tumor Treating Fields (TTF) devices, not chemotherapy drug development. The observation remains preliminary (animal models, bioRxiv pre-print) and would require substantial additional clinical validation to influence treatment protocols or competitive positioning. Investors should note this does not materially affect NVCR's glioblastoma or other TTF-indicated cancer franchises, though any evidence of improved quality-of-life outcomes with standard-of-care chemotherapy could modestly enhance the value proposition of TTF combination therapies if validated clinically.
Start free trial for share counts, dollar values & AI analysis
44 more position changes — start your free trial to see dollar values and AI analysis for all of them.
Track specialist biotech funds, insider signals, and AI analysis
Start 14-Day Free TrialGet free weekly alerts on fund moves and catalysts: